Business
Liberum Appointed as Nominated Adviser & Broker
Liberum Appointed as Nominated Adviser & Broker.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 9076Z Futura Medical PLC 23 May 2019 \n\nFutura Medical\n \nAppointment of Liberum as Nominated Adviser and Broker\n \n23 May 2019\n \nFutura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces the appointment, with immediate effect, of Liberum Capital Limited (\"Liberum\") as its Nominated Adviser and sole Broker.\n \nENDS\n \nFor further information please contact:\n \nFutura Medical plc \nJames Barder, Chief Executive\nAngela Hildreth, Finance Director and COO\nEmail: [email protected]\nTel: +44 (0) 1483 685 670\n \nNominated Adviser and Broker:\nLiberum\nBidhi Bhoma\nEuan Brown\nKane Collings\nTel: +44 (0) 20 3100 2000\n \nFor media enquiries please contact:\nOptimum Strategic Communications\nMary Clark/ Hollie Vile/ Ellie Blackwell\nEmail: [email protected]\nTel: +44 (0) 203 950 9144\n \nNotes to editors\n \nAbout Futura Medical plc\nFutura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.\n \nFutura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com\n \n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END APPQLLFLKEFFBBK\n ","length":3511,"tagName":"div"}]